Author:
Tokuhira Michihide,Tamaru Jun-ichi,Kizaki Masahiro
Publisher
Japanese Society for Lymphoreticular Tissue Research
Reference179 articles.
1. 1 Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders. revised 4th ed, IARC publications. 2017; pp. 443-464.
2. 2 Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Immunodeficiency-associated lymphoproliferative disorders. 4th ed, IARC publications. 2008. pp. 335-351.
3. 3 Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective. Mod Rheumatol. 2018; 28: 1-8.
4. 4 Balandraud N, Guis S, Baptiste Meynard J et al. Long-term treatment with methotrexate or tumor necrosis factor α inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57: 762-767.
5. 5 Yoshida Y, Takahashi Y, Yamashita H et al. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014; 24: 763-765.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献